New York, June 21, 2016 -- Moody's Investors Service assigned a B1 Corporate Family Rating and B1-PD Probability of Default Rating to Arbor Pharmaceuticals, LLC ("Arbor"). Moody's also assigned a B1 rating to the proposed $575 million senior secured bank credit facility. The proceeds of the term loan, along with cash on hand, will be used to fund the pending acquisition of XenoPort, Inc. for approximately $467 million. The outlook is stable. This is the first time that Moody's has rated Arbor.
Vollständigen Artikel bei Moodys lesen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.